Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Animal Models

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Animal Model: NMDA Receptor Antagonist Rx (MK801, PCP, Ketamine)-Acute
Preparation Type: Drug-Induced Preparations
DA-related behavior: Increases locomotor activity and stereotopy, ataxia
Gating: Disrupted PPI 1 day after PCP, and 15 minutes after PCP, but not 7 or 28 days later, abnormal latent inhibition
Cognitive behavior: Decreased working memory, disrupted fear conditioning, long-term spatial memory deficits, impaired passive-avoidance, recognition memory deficit
Social behavior: Impaired social interaction
Molecular/morphological signature: Impaired LTP, decreased AMPA receptor density
Response to APD: Enhanced locomotor responses blocked by APD, glycine transporter-1 inhibition rescues LTP, PPI disruption attenuated by admatine, glycine, D-serine, not D-cycloserine, fear conditioning disruption prevented by clozapine, but not haloperidol, LI abnormalities reversed by risperidone and M100907, passive avoidance impairment reversed by lurasidone, recognition memory deficit reversed by clozapine and D-serine, but not haloperidol

November 24, 2014
SRF News
SRF Comments
Text Size
Reset Text Size

See our latest webinar, Cognition and Treatment Resistance in Schizophrenia, held November 10, 2014.

See our last webinar, Research Domain Criteria (RDoC) Applied to Verbal Hallucinations, held May 28, 2014.

Check out our Schizophrenia Bulletin Forum Discussion: Prefrontal Inefficiency Is Associated With Polygenic Risk for Schizophrenia.
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright